-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $100

Benzinga·02/17/2026 11:40:08
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $90 to $100.